Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (TORCH)

Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane

Phase II trial of oxaliplatin in combination with S-1(SOX) in patients with recurrent or metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline and taxane

Study Overview

• Status: Completed
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: TS-1 and Eloxatin

Detailed Description

The main purpose of this study is to find out the efficacy and safety profile of TS-1 with oxaliplatin in previously anthracycline and taxane pretreated patients.

• Study Type: Interventional
• Enrollment (Actual): 87
• Phase: Phase 2

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 110-744
    • Seoul National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• M/F age ≥ 18
• Metastatic(TxNxM1) or inoperable locally recurrent breast cancer(rT4NxM0) after taxane & anthracycline therapy
• Measurable disease (RECIST) : A patient with at least one measurable lesion of which the diameter is confirmed to be 10mm in spiral CT or multidetector CT (MD CT), or 20 mm or longer in conventional CT
• No prior treatment with S-1, capecitabine, platinum In metastatic setting
• Must have received an anthracycline and taxane in adj. or metastatic settings (concurrent, sequential, or combined with other drugs)

• For taxanes (Paclitaxel (P) / Docetaxel (D))

  1. Must have progressed while or after receiving P or D (Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease)
  2. Only 1 adjuvant regimen permitted (neoadjuvant immediately followed by surgery and immediately followed by adj. is permitted)

• For anthracyclines

  1. Progressed while on anthracycline treatment, with or without initial response or
  2. Have received an adequate course of anthracyclines defined as follows:
  1. Adj.: Must have received a standard regimen (doxorubicin ≥ 240 mg/m2 or ≥ 360 mg/m2 epirubicin or equivalent)
  2. Metastatic: Must have received a standard regimen(doxorubicin ≥300mg/m2 or equivalent)
• Not candidate for Herceptin
• ECOG PS ≤ 2
• Completion of all prior chemotherapy ≥ 3 wks prior to enrol
• Completion of hormonal therapy 2 wks prior to enroll
• Resolution of all clinically significant toxic effects (excluding alopecia and sensory neuropathies) of any prior surgery or therapy to grade ≤ 1 (NCI CTCAE 3.0), for peripheral neuropathy grade ≤ 2 (NCI CTCAE 3.0), or to within the limits listed in the specific inclusion/exclusion criteria
• A patient with the willingness to comply with the study protocol during the study period and capable of complying with it.
• Informed consent obtained.

Exclusion Criteria:

• WOCBP(woman of child bearing potential) unwilling to use acceptable method to avoid pregnancy
• Breast feeding or pregnant women
• Patients with Hx of symptomatic brain or leptomeningeal involvement (eligible if asymptomatic 2weeks after proper radiation therapy)
• ≥grade 3 neuropathy currently
• Hx of second malignancy except adequately treated basal or squamous skin ca or CIS of cervix. Adequately treated contralateral breast ca with DF >5 yrs prior to this study is permitted
• MI, unstable angina, CABG, clinically significant arrhythmia within 6 mo
• Hx of inflammatory bowel disease or chronic diarrhea,
• ANC < 1500, Plt < 100K, Hb <9.0
• Ccr < 60 ml/min or creatinine >1.5
• Bil > 1.5 x UNL, AST/ALT ≥ 2.5xUNL if hepatic meta + > 5xUNL)
• History of hypersensitivity to 5-FU, platinum, or to compounds with similar chemical structures
• More than 3 prior chemotherapy for metastatic or recurrent disease or prior treatment with S-1, capecitabine or any platinum analogs in metastatic setting (5-FU combine with other agent in metastatic setting is allowed_ ex) CMF, FAC)
• Her2(+) pts who are candidates for Herceptin
• prior surgery within 4 week
• participate in other clinical trials within 4 week
• prior radiation therapy within 2 week

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Response Rate	TTP, OS

Secondary Outcome Measures

Outcome Measure	Time Frame
- To determine the time to progression - To determine the response duration - To determine the overall survival - To determine toxicities - To determine the pharmacogenomic predictor (association study)	PFS, OS

Collaborators and Investigators

• Sponsor: Seoul National University Hospital
• Collaborators: National Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul National University Bundang Hospital; Severance Hospital; Korean Cancer Study Group
• Investigators: Principal Investigator: Seock-Ah Im, MD, PhD, Seoul National University Hospital

Publications and helpful links

Helpful Links

• Korean Cancer Study Group
• Seoul National University Hospital Clinical Trial Center

Study record dates

Study Major Dates

• Study Start: September 1, 2007
• Primary Completion (Actual): October 1, 2013
• Study Completion (Actual): October 1, 2013

Study Registration Dates

• First Submitted: September 8, 2007
• First Submitted That Met QC Criteria: September 8, 2007
• First Posted (Estimate): September 11, 2007

Study Record Updates

• Last Update Posted (Estimate): October 10, 2013
• Last Update Submitted That Met QC Criteria: October 9, 2013
• Last Verified: October 1, 2013

More Information

Terms related to this study

• Keywords: Breast Neoplasms; Oxaliplatin; S1
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Oxaliplatin
• Other Study ID Numbers: KCSG-BR-0703, H-0706-009-209